SCHEMBL3846516

SCHEMBL3846516

Fc1ccc(-c2n[nH]cc2-c2ccc3ncnc(N4CCc5ccccc5C4)c3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 11/20 0.50
KDM4E B2RXH2 8/20 0.50
NPSR1 Q6W5P4 4/20 0.50
HTT P42858 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPK1 P28482 8/20 0.48
MAPT P10636 5/20 0.48
NR2F2 P24468 2/20 0.48
POLB P06746 1/20 0.48
RAB9A P51151 1/20 0.48
CYP1A2 P05177 11/20 0.47
CYP3A4 P08684 11/20 0.47
ALDH1A1 P00352 11/20 0.47
CYP2C19 P33261 9/20 0.47
HIF1A Q16665 8/20 0.47
TSHR P16473 8/20 0.47
KMT2A Q03164 7/20 0.47
MEN1 O00255 6/20 0.47
HPGD P15428 5/20 0.47
CYP2D6 P10635 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3848700 0.85 CYP3A4 (0.48) LMNAKDM4EHTTSMN1; SMN2MAPK1
SCHEMBL3853682 0.85 CYP1A2 (0.52) LMNAKDM4ENPSR1HTTSMN1; SMN2
SCHEMBL3848419 0.84 CYP3A4 (0.63) LMNAKDM4EHTTSMN1; SMN2MAPK1
SCHEMBL3845114 0.83 CYP3A4 (0.52) LMNAKDM4ENPSR1HTTSMN1; SMN2
SCHEMBL3849265 0.81 CYP3A4 (0.56) LMNAKDM4EHTTSMN1; SMN2MAPK1
SCHEMBL3849667 0.81 CYP3A4 (0.50) LMNAKDM4ESMN1; SMN2MAPK1MAPT
SCHEMBL3848383 0.80 CYP1A2 (0.48) LMNAKDM4EHTTSMN1; SMN2MAPK1
SCHEMBL3846990 0.80 ACHE (0.54) LMNAKDM4EHTTSMN1; SMN2MAPK1
SCHEMBL3849819 0.79 ACHE (0.50) LMNAKDM4EHTTSMN1; SMN2MAPK1
SCHEMBL3856130 0.78 AKT1 (0.50) LMNAKDM4ENPSR1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2048142-A2 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof Eisai R&D Management Co., Ltd. (JP) 2009-04-15 EP disclosed
EP-1382603-B1 NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF EISAI R&D MAN CO LTD (JP) 2008-07-23 EP disclosed
US-7074801-B1 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof EISAI CO., LTD. (JP) 2006-07-11 US disclosed
EP-1382603-A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-01-21 EP disclosed